Megan Dixon , Tuan Anh Phan , J.C. Dallon , Jianjun Paul Tian
{"title":"Mathematical model for IL-2-based cancer immunotherapy","authors":"Megan Dixon , Tuan Anh Phan , J.C. Dallon , Jianjun Paul Tian","doi":"10.1016/j.mbs.2024.109187","DOIUrl":null,"url":null,"abstract":"<div><p>A basic mathematical model for IL-2-based cancer immunotherapy is proposed and studied. Our analysis shows that the outcome of therapy is mainly determined by three parameters, the relative death rate of CD<span><math><msup><mrow><mn>4</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> T cells, the relative death rate of CD<span><math><msup><mrow><mn>8</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> T cells, and the dose of IL-2 treatment. Minimal equilibrium tumor size can be reached with a large dose of IL-2 in the case that CD<span><math><msup><mrow><mn>4</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> T cells die out. However, in cases where CD<span><math><msup><mrow><mn>4</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> and CD<span><math><msup><mrow><mn>8</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> T cells persist, the final tumor size is independent of the IL-2 dose and is given by the relative death rate of CD<span><math><msup><mrow><mn>4</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> T cells. Two groups of in silico clinical trials show some short-term behaviors of IL-2 treatment. IL-2 administration can slow the proliferation of CD<span><math><msup><mrow><mn>4</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> T cells, while high doses for a short period of time over several days transiently increase the population of CD<span><math><msup><mrow><mn>8</mn></mrow><mrow><mo>+</mo></mrow></msup></math></span> T cells during treatment before it recedes to its equilibrium. IL-2 administration for a short period of time over many days suppresses the tumor population for a longer time before approaching its steady-state levels. This implies that intermittent administration of IL-2 may be a good strategy for controlling tumor size.</p></div>","PeriodicalId":51119,"journal":{"name":"Mathematical Biosciences","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mathematical Biosciences","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0025556424000476","RegionNum":4,"RegionCategory":"数学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A basic mathematical model for IL-2-based cancer immunotherapy is proposed and studied. Our analysis shows that the outcome of therapy is mainly determined by three parameters, the relative death rate of CD T cells, the relative death rate of CD T cells, and the dose of IL-2 treatment. Minimal equilibrium tumor size can be reached with a large dose of IL-2 in the case that CD T cells die out. However, in cases where CD and CD T cells persist, the final tumor size is independent of the IL-2 dose and is given by the relative death rate of CD T cells. Two groups of in silico clinical trials show some short-term behaviors of IL-2 treatment. IL-2 administration can slow the proliferation of CD T cells, while high doses for a short period of time over several days transiently increase the population of CD T cells during treatment before it recedes to its equilibrium. IL-2 administration for a short period of time over many days suppresses the tumor population for a longer time before approaching its steady-state levels. This implies that intermittent administration of IL-2 may be a good strategy for controlling tumor size.
期刊介绍:
Mathematical Biosciences publishes work providing new concepts or new understanding of biological systems using mathematical models, or methodological articles likely to find application to multiple biological systems. Papers are expected to present a major research finding of broad significance for the biological sciences, or mathematical biology. Mathematical Biosciences welcomes original research articles, letters, reviews and perspectives.